Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica A Pollard

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2020
Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology GroupKelly D Getz, Lillian Sung, Todd A Alonzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2015
Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology GroupKatherine Tarlock, Todd A Alonzo, Robert B Gerbing, et al.
Blood|March 2, 2012
Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AMLJessica A Pollard, Todd A Alonzo, Michael Loken, et al.
Medrxiv : the Preprint Server for Health Sciences|August 6, 2025
Germline Variant Burden Warrants Universal Genetic Testing in Pediatric Myeloid LeukemiaLauren M Harmon, Zachary S Hattig, Yizhou Peter Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2021
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric <i>KMT2A</i>-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531Jessica A Pollard, Erin Guest, Todd A Alonzo, et al.
Transplantation and Cellular Therapy|June 18, 2022
Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular TherapyKatherine Tarlock, Maria Luisa Sulis, Joseph H Chewning, et al.
Blood|April 24, 2010
Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology GroupPhoenix A Ho, Rong Zeng, Todd A Alonzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology groupPhoenix A Ho, Julia Kuhn, Robert B Gerbing, et al.
Pediatric Blood & Cancer|February 10, 2015
Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemiaKatherine Tarlock, Bill Chang, Todd Cooper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2017
CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531Jatinder K Lamba, Lata Chauhan, Miyoung Shin, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2020
Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology GroupKelly D Getz, Lillian Sung, Todd A Alonzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2015
Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology GroupKatherine Tarlock, Todd A Alonzo, Robert B Gerbing, et al.
Blood|March 2, 2012
Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AMLJessica A Pollard, Todd A Alonzo, Michael Loken, et al.
Medrxiv : the Preprint Server for Health Sciences|August 6, 2025
Germline Variant Burden Warrants Universal Genetic Testing in Pediatric Myeloid LeukemiaLauren M Harmon, Zachary S Hattig, Yizhou Peter Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2021
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric <i>KMT2A</i>-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531Jessica A Pollard, Erin Guest, Todd A Alonzo, et al.
Transplantation and Cellular Therapy|June 18, 2022
Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular TherapyKatherine Tarlock, Maria Luisa Sulis, Joseph H Chewning, et al.
Blood|April 24, 2010
Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology GroupPhoenix A Ho, Rong Zeng, Todd A Alonzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology groupPhoenix A Ho, Julia Kuhn, Robert B Gerbing, et al.
Pediatric Blood & Cancer|February 10, 2015
Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemiaKatherine Tarlock, Bill Chang, Todd Cooper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2017
CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531Jatinder K Lamba, Lata Chauhan, Miyoung Shin, et al.
Pageof 4